Literature DB >> 19167697

Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review.

Benjamin K S Chan1, Joy Melnikow, Christina A Slee, Rose Arellanes, George F Sawaya.   

Abstract

OBJECTIVE: We conducted a systematic review to evaluate the characteristics of human papillomavirus testing, particularly Hybrid Capture 2, in follow-up evaluations after treatment for cervical intraepithelial neoplasia for the detection of residual or recurrent cervical intraepithelial neoplasia grade >/= 2. STUDY
DESIGN: Medline was searched for relevant studies that were published between 1992 and September 2007. Of the 1107 citations that were identified, 20 articles met the inclusion criteria.
RESULTS: Studies that used polymerase chain reaction testing were too heterogeneous to combine. We identified 5 studies that performed both Hybrid Capture 2 and colposcopy. Pooled sensitivity for Hybrid Capture 2 was 90.7% (95% CI, 75.4-96.9%), and pooled specificity was 74.6% (95% CI, 60.4-85.0%). Pooled sensitivity for cervical cytologic testing was 76.6% (95% CI, 62.0-86.8%), and pooled specificity was 89.7% (95% CI, 22.7-99.6%).
CONCLUSION: Hybrid Capture 2 testing can identify approximately 91% of women with residual or recurrent cervical intraepithelial neoplasia grade >/= 2; however, approximately 30% of women would undergo colposcopy in follow-up evaluation.

Entities:  

Mesh:

Year:  2009        PMID: 19167697      PMCID: PMC2784953          DOI: 10.1016/j.ajog.2008.11.031

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  52 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Is high-risk human papillomavirus infection associated with cervical intraepithelial neoplasia eliminated after conization by large-loop excision of the transformation zone?

Authors:  E Kucera; G Sliutz; K Czerwenka; G Breitenecker; S Leodolter; A Reinthaller
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2001-12-10       Impact factor: 2.435

3.  The role of genotype-specific human papillomavirus detection in diagnosing residual cervical intraepithelial neoplasia.

Authors:  Ruud L M Bekkers; Willem J G Melchers; Judith M J E Bakkers; Antonius G J M Hanselaar; Wim G V Quint; Henk Boonstra; Leon F A G Massuger
Journal:  Int J Cancer       Date:  2002-11-10       Impact factor: 7.396

4.  Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia.

Authors:  Kristina Elfgren; Marcel Jacobs; Jan M M Walboomers; Chris J L M Meijer; Joakim Dillner
Journal:  Obstet Gynecol       Date:  2002-11       Impact factor: 7.661

5.  Persistent human papillomavirus infection and smoking increase risk of failure of treatment of cervical intraepithelial neoplasia (CIN).

Authors:  Nabil Nathan Acladious; Chrostopher Sutton; Debbi Mandal; Rami Hopkins; Magid Zaklama; Henery Kitchener
Journal:  Int J Cancer       Date:  2002-03-20       Impact factor: 7.396

6.  Margin clearance and HPV infection do not influence the cure rates of early neoplasia of the uterine cervix by laser conization.

Authors:  T Izumi; N Kyushima; T Genda; N Kobayashi; T Kanai; K Wakita; H Kuramoto
Journal:  Eur J Gynaecol Oncol       Date:  2000       Impact factor: 0.196

7.  Human papillomavirus testing and the outcome of treatment for cervical intraepithelial neoplasia.

Authors:  E Paraskevaidis; G Koliopoulos; Y Alamanos; V Malamou-Mitsi; E D Lolis; H C Kitchener
Journal:  Obstet Gynecol       Date:  2001-11       Impact factor: 7.661

8.  A prospective Swedish cohort study on psychosocial factors influencing anxiety in women referred for colposcopy.

Authors:  C Hellsten; K Sjöström; P G Lindqvist
Journal:  BJOG       Date:  2007-01       Impact factor: 6.531

9.  Persistent infection with human papillomavirus following the successful treatment of high grade cervical intraepithelial neoplasia.

Authors:  Margaret E Cruickshank; Linda Sharp; George Chambers; Louise Smart; Graeme Murray
Journal:  BJOG       Date:  2002-05       Impact factor: 6.531

10.  Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia.

Authors:  M A Nobbenhuis; C J Meijer; A J van den Brule; L Rozendaal; F J Voorhorst; E K Risse; R H Verheijen; T J Helmerhorst
Journal:  Br J Cancer       Date:  2001-03-23       Impact factor: 7.640

View more
  10 in total

1.  Clinical significance of atypical squamous cells of undetermined significance after treatment for cervical intraepithelial grade 3 neoplasia: A retrospective single-center cohort study.

Authors:  Toshimichi Onuma; Kimihisa Tajima; Kumiko Sato; Katsushige Hattori; Shin Fukuda; Takahiro Tsuji; Yoshio Yoshida
Journal:  Mol Clin Oncol       Date:  2017-10-04

2.  Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment.

Authors:  Aimée R Kreimer; Mark Schiffman; Rolando Herrero; Allan Hildesheim; Paula González; Robert D Burk; Carolina Porras; Mark E Sherman; Franklin Demuth; Li Cheung; Concepción Bratti; Ana Cecilia Rodríguez
Journal:  Int J Cancer       Date:  2011-08-30       Impact factor: 7.396

Review 3.  Current Status of Human Papillomavirus Infection and Cervical Cancer in the Philippines.

Authors:  Ryan C V Lintao; Leslie Faye T Cando; Glenmarie Angelica S Perias; Ourlad Alzeus G Tantengco; Ian Kim B Tabios; Clarissa L Velayo; Sheriah Laine M de Paz-Silava
Journal:  Front Med (Lausanne)       Date:  2022-06-20

4.  Optimizing technology for cervical cancer screening in high-resource settings.

Authors:  Lyndsay A Richardson; Joseph Tota; Eduardo L Franco
Journal:  Expert Rev Obstet Gynecol       Date:  2011-05

5.  Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study.

Authors:  Joy Melnikow; Colleen McGahan; George F Sawaya; Thomas Ehlen; Andrew Coldman
Journal:  J Natl Cancer Inst       Date:  2009-05-12       Impact factor: 13.506

6.  Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.

Authors:  Hormuzd A Katki; Mark Schiffman; Philip E Castle; Barbara Fetterman; Nancy E Poitras; Thomas Lorey; Li C Cheung; Tina Raine-Bennett; Julia C Gage; Walter K Kinney
Journal:  J Low Genit Tract Dis       Date:  2013-04       Impact factor: 1.925

7.  Posttreatment human papillomavirus testing for residual or recurrent high-grade cervical intraepithelial neoplasia: a pooled analysis.

Authors:  Mamiko Onuki; Koji Matsumoto; Manabu Sakurai; Hiroyuki Ochi; Takeo Minaguchi; Toyomi Satoh; Hiroyuki Yoshikawa
Journal:  J Gynecol Oncol       Date:  2015-10-08       Impact factor: 4.401

Review 8.  HPV-Testing in Follow-up of Patients Treated for CIN2+ Lesions.

Authors:  Luciano Mariani; Maria Teresa Sandri; Mario Preti; Massimo Origoni; Silvano Costa; Paolo Cristoforoni; Fabio Bottari; Mario Sideri
Journal:  J Cancer       Date:  2016-01-01       Impact factor: 4.207

9.  Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: economic analysis from NHS Sentinel Sites Study.

Authors:  Rosa Legood; Megan Smith; Jie-Bin Lew; Robert Walker; Sue Moss; Henry Kitchener; Julietta Patnick; Karen Canfell
Journal:  BMJ       Date:  2012-10-31

10.  Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial.

Authors:  Suzanne M Garland; Jorma Paavonen; Unnop Jaisamrarn; Paulo Naud; Jorge Salmerón; Song-Nan Chow; Dan Apter; Xavier Castellsagué; Júlio C Teixeira; S Rachel Skinner; James Hedrick; Genara Limson; Tino F Schwarz; Willy A J Poppe; F Xavier Bosch; Newton S de Carvalho; Maria Julieta V Germar; Klaus Peters; M Rowena Del Rosario-Raymundo; Grégory Catteau; Dominique Descamps; Frank Struyf; Matti Lehtinen; Gary Dubin
Journal:  Int J Cancer       Date:  2016-09-09       Impact factor: 7.396

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.